TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19586145

Group type: EXPERIMENTAL
Intervention: Initial-Winning condition
Number of subjects: 179

Group type: COMPARATOR
Intervention: Initial-Losing condition
Number of subjects: 179
Study: 18087552

Group type: EXPERIMENTAL
Intervention: Verapamil (480 mg/d)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Metoprolol (50 mg/d)
Number of subjects: 60
Study: 15476904

Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg once daily for 12 months
Number of subjects: 116

Group type: COMPARATOR
Intervention: Nifedipine GITS 20 mg once daily for 12 months
Number of subjects: 116
Study: 11810363

Group type: EXPERIMENTAL
Intervention: Ketamine 0.15 mg/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 80
Study: 9916610

Group type: EXPERIMENTAL
Intervention: Timolol maleate ophthalmic gel-forming solution 0.5% QD
Number of subjects: 152

Group type: COMPARATOR
Intervention: Levobunolol hydrochloride 0.5% BID
Number of subjects: 152
Study: 7482139

Group type: EXPERIMENTAL
Intervention: Surgical gloves
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glove leak and contamination studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 2707923

Group type: EXPERIMENTAL
Intervention: 500 mg oral ciprofloxacin
Number of subjects: 6

Group type: COMPARATOR
Intervention: 200 mg intravenous ciprofloxacin
Number of subjects: 6
Study: 665536

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Not applicable (inoperable patients)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Not applicable (patients without significant coronary artery disease)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Not applicable (incidence rate)
Number of subjects: 50
Study: 31883370

Group type: EXPERIMENTAL
Intervention: Bezlotoxumab
Number of subjects: 168

Group type: COMPARATOR
Intervention: Actoxumab + Bezlotoxumab
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 31135960

Group type: EXPERIMENTAL
Intervention: Full-field digital mammography (FFDM)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Digital breast tomosynthesis (DBT)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Synthetic mammography (SM)
Number of subjects: 9
Study: 27935735

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (LDX) 70 mg/day for 5 weeks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: d-amphetamine (active moiety of LDX)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (single-blind for 1 week prior to LDX)
Number of subjects: 21
Study: 25937506

Group type: EXPERIMENTAL
Intervention: Team Up for Healthy Living curriculum (intervention) consisting of eight 40-minute sessions focusing on nutrition awareness, physical activity, leadership, and communication.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lifetime Wellness curriculum (control) regularly scheduled at control schools.
Number of subjects: 10
Study: 25070447

Group type: EXPERIMENTAL
Intervention: Microbial immune enteral nutrition
Number of subjects: 96
Study: 21952094

Group type: EXPERIMENTAL
Intervention: IFNβ‐1b 250 µg
Number of subjects: 2244

Group type: EXPERIMENTAL
Intervention: IFNβ‐1b 500 µg
Number of subjects: 2244

Group type: EXPERIMENTAL
Intervention: IFNβ‐1b 250 µg and 500 µg
Number of subjects: 2244

Group type: COMPARATOR
Intervention: Control (Glatiramer acetate 20 mg)
Number of subjects: 2244
Study: 19254906

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (400 microg/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 44

Group type: COMPARATOR
Intervention: Inhaled budesonide and Placebo
Number of subjects: 44
Study: 18091071

Group type: EXPERIMENTAL
Intervention: Bromocriptine (dopamine agonist)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 15302228

Group type: EXPERIMENTAL
Intervention: 20 mg beta‐methyl‐6‐chloromelatonin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 35 mg beta‐methyl‐6‐chloromelatonin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 50 mg beta‐methyl‐6‐chloromelatonin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 100 mg beta‐methyl‐6‐chloromelatonin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: All doses of beta‐methyl‐6‐chloromelatonin
Number of subjects: 8
Study: 11587162

Group type: EXPERIMENTAL
Intervention: Immediate smoking cessation (n=19)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Wait list control group (n=15)
Number of subjects: 66
Study: 10223498

Group type: EXPERIMENTAL
Intervention: 25 mg sildenafil
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: 100 mg sildenafil
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: sildenafil (all doses)
Number of subjects: 514

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 514
Study: 7851353

Group type: EXPERIMENTAL
Intervention: Sustained release metoclopramide (Gastromax 30 mg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 2520372

Group type: EXPERIMENTAL
Intervention: Topical corticosteroid treatment under occlusive dressings for 72 hours
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 8
Study: 17894041

Group type: EXPERIMENTAL
Intervention: High dose thiothixene (40 mg.)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low dose thiothixene (10 mg.)
Number of subjects: 40
Study: 30635704

Group type: EXPERIMENTAL
Intervention: tDCS with anode on left STG/cathode on right shoulder
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: tDCS with anode on left STG/cathode on right STG
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham (placebo)
Number of subjects: 17
Study: 28490942

Group type: EXPERIMENTAL
Intervention: Medial approach
Number of subjects: 139

Group type: COMPARATOR
Intervention: Lateral approach
Number of subjects: 139
Study: 26069137

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg (Group A)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg (Group B)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 73
Study: 23276416

Group type: EXPERIMENTAL
Intervention: Press-fit technique
Number of subjects: 69

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 69
Study: 21586502

Group type: EXPERIMENTAL
Intervention: Early Intensive Behavioral Intervention (EIBI)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: University-supervised interventions
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Parent-commissioned interventions
Number of subjects: 41
Study: 18263688

Group type: EXPERIMENTAL
Intervention: EBUS-TBNA with one aspiration
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: EBUS-TBNA with two aspirations
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: EBUS-TBNA with three aspirations
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: EBUS-TBNA with four aspirations
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: EBUS-TBNA with first or second aspiration obtaining at least one tissue core
Number of subjects: 102

Group type: COMPARATOR
Intervention: EBUS-TBNA
Number of subjects: 102
Study: 16857887

Group type: EXPERIMENTAL
Intervention: 600 mg of micronized progesterone vaginally (progesterone group)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: 600 mg of micronized progesterone and 4 mg of E2 valerate orally (progesterone/E2 group)
Number of subjects: 201
Study: 11274517

Group type: EXPERIMENTAL
Intervention: Group randomized trials (GRTs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various analytic methods for GRTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Design issues in GRTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Real data example
Number of subjects: 0
Study: 9283776

Group type: EXPERIMENTAL
Intervention: Extended insulin regimen (5 U/h continued until resolution of hyperketonemia)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Extended insulin regimen
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional insulin regimen (5 U/h until near-normoglycemia, then reduced rate)
Number of subjects: 22
Study: 7849344

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 141
Study: 3051043

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel (1 mg initial dose, followed by 1 mg or 2 mg 6 hours later if needed)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous perfusion of synthetic oxytocin (starting at 1 mU/min, increased every 20 minutes)
Number of subjects: 50
Study: 31092363

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 1532

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 1532
Study: 28316072

Group type: EXPERIMENTAL
Intervention: Low-calorie DASH diet
Number of subjects: 60
Study: 24443001

Group type: EXPERIMENTAL
Intervention: 3×1000 mg rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22921855

Group type: EXPERIMENTAL
Intervention: Terlipressin (TP) administered as a continuous intravenous dose of 1.3 μg/kg/h
Number of subjects: 32

Group type: COMPARATOR
Intervention: Dopamine administered in doses up to 20 μg/kg/min
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups were monitored for hemodynamic changes and PaO(2)/FiO(2) ratio
Number of subjects: 32
Study: 21399391

Group type: EXPERIMENTAL
Intervention: 200 mg CoQ10 daily
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 19615314

Group type: EXPERIMENTAL
Intervention: Western medicine plus American ginseng and Salviae miltiorrhizae preparations
Number of subjects: 35

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 35
Study: 16638761

Group type: EXPERIMENTAL
Intervention: Global functional impairment
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Cognitive impairment
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Impaired manual dexterity
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Visuospatial dysfunction
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 245
Study: 12883913

Group type: EXPERIMENTAL
Intervention: Acrylic hydrophobic IOL (Acrysof MA30BA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Heparin surface-modified polymethylmethacrylate IOL (Pharmacia & Upjohn 809C)
Number of subjects: 36
Study: 10594199

Group type: EXPERIMENTAL
Intervention: VATS lobectomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional lobectomy (open thoracotomy)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Open lobectomy
Number of subjects: 100
Study: 9068769

Group type: EXPERIMENTAL
Intervention: Amisulpride (100 mg/day)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 8439073

Group type: EXPERIMENTAL
Intervention: Experimental group (n = 40) discharged with weights < or = 2.000 gm
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (n = 40) discharged with weights > or = 2.000 gm
Number of subjects: 80
Study: 3303402

Group type: EXPERIMENTAL
Intervention: Partial ileal bypass (PIB)
Number of subjects: 838

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 838
Study: 31908205

Group type: COMPARATOR
Intervention: Cigarette packs with no targeting
Number of subjects: 954

Group type: EXPERIMENTAL
Intervention: Cigarette packs with subtle targeting
Number of subjects: 954

Group type: EXPERIMENTAL
Intervention: Rainbow 'pride edition' cigarette packs
Number of subjects: 954
Study: 30428933

Group type: EXPERIMENTAL
Intervention: TPD health warnings
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Comparative harm message (COMP)
Number of subjects: 2400

Group type: COMPARATOR
Intervention: TPD presence (TPD1 vs. TPD2 vs. No-TPD)
Number of subjects: 2400

Group type: COMPARATOR
Intervention: COMP presence (Presence vs. Absence)
Number of subjects: 2400
Study: 25651896

Group type: EXPERIMENTAL
Intervention: Backs
Number of subjects: 41
Study: 25796161

Group type: COMPARATOR
Intervention: Methylprednisolone (MP)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Ganglioside (GM) combined with Methylprednisolone (MP)
Number of subjects: 53
Study: 24055415

Group type: EXPERIMENTAL
Intervention: 41.6 Gy in 13 fractions over 5 weeks
Number of subjects: 4441

Group type: EXPERIMENTAL
Intervention: 39 Gy in 13 fractions over 5 weeks
Number of subjects: 4441

Group type: COMPARATOR
Intervention: 50 Gy in 25 fractions over 5 weeks
Number of subjects: 4441

Group type: EXPERIMENTAL
Intervention: 40 Gy in 15 fractions over 3 weeks
Number of subjects: 4441
Study: 20935692

Group type: EXPERIMENTAL
Intervention: Topical diclofenac (n = 9)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Topical ketorolac (n = 11)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Topical diclofenac (n = 8)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Topical ketorolac (n = 9)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Topical diclofenac
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Topical ketorolac
Number of subjects: 37
Study: 17785764

Group type: EXPERIMENTAL
Intervention: Panitumumab 6 mg/kg every 2 weeks
Number of subjects: 176

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 176
Study: 16843157

Group type: EXPERIMENTAL
Intervention: Stepwise rotational osteotomy and fixation of the ulna followed by the radius
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rotating the radius followed by the ulna
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rotating the radius alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ulna osteotomy alone
Number of subjects: 10
Study: 12970516

Group type: EXPERIMENTAL
Intervention: donepezil 5 mg/d
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: donepezil 10 mg/d
Number of subjects: 603

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 603
Study: 10994000

Group type: EXPERIMENTAL
Intervention: Acetyl-l-carnitine (ALCAR) 1 g tid
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study: 8778893

Group type: EXPERIMENTAL
Intervention: Experiment 1 (intercepting a moving spot on a computer screen)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Experiment 2 (intercepting a moving table tennis ball)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Experiment 3 (hitting a ball to reach a moving human target)
Number of subjects: 51
Study: 1814984

Group type: EXPERIMENTAL
Intervention: Marco MT‐336 automated perimeter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Goldmann‐type manual kinetic perimetry
Number of subjects: 0
Study: 6303209

Group type: EXPERIMENTAL
Intervention: Cefmenoxime (1.0 g)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Procaine penicillin G (4.8 X 10(6) U) + probenecid (1.0 g orally)
Number of subjects: 121
Study: 31801620

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 712

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg and 150 mg
Number of subjects: 712
Study: 30235387

Group type: EXPERIMENTAL
Intervention: Sarecycline 1.5 mg/kg/day
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000
Study: 28586585

Group type: EXPERIMENTAL
Intervention: Local Anaesthesia (LA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: General Anaesthesia (GA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 60
Study: 24569263

Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg once daily
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Dasatinib 50 mg twice daily
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Dasatinib 140 mg once daily
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Dasatinib 70 mg twice daily
Number of subjects: 670
Study: 22353558

Group type: EXPERIMENTAL
Intervention: Physical Activity Scale for the Elderly (PASE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Actigraph GT1M accelerometer
Number of subjects: 40

Group type: COMPARATOR
Intervention: International Physical Activity Questionnaire (IPAQ)
Number of subjects: 40
Study: 21455450

Group type: EXPERIMENTAL
Intervention: Agnikarma (cauterization treatment)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Katibasti
Number of subjects: 40
Study: 17878472

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 16351563

Group type: EXPERIMENTAL
Intervention: L-arginine supplementation
Number of subjects: 7
Study: 12409756

Group type: EXPERIMENTAL
Intervention: Customized pharyngeal flap
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sphincter pharyngoplasty
Number of subjects: 50
Study: 10467966

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study: 7880187

Group type: EXPERIMENTAL
Intervention: Prednisone (15 mg/day for 1 month, tapered thereafter)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 56
Study: 2120362

Group type: EXPERIMENTAL
Intervention: Conventional mandibular block injection technique
Number of subjects: 200

Group type: COMPARATOR
Intervention: Closed-mouth mandibular block injection technique
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 200
Study: 232043

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31144389

Group type: EXPERIMENTAL
Intervention: High risk of shift work disorder
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Shift work disorder, number of night shifts, and alcoholic drinks on non-work days
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Depression and years of shift work
Number of subjects: 202
Study: 30395687

Group type: EXPERIMENTAL
Intervention: Baseline vertebral fractures (VF) detected by lateral spine imaging (LSI)
Number of subjects: 1084
Study: 31473729

Group type: EXPERIMENTAL
Intervention: 0.05% cetylpyridinium chloride
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tempered rinses at 47ºC
Number of subjects: 40
Study: 25497165

Group type: EXPERIMENTAL
Intervention: Mechanical tissue removal system (TRUCLEAR 5.0 System)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Bipolar electrosurgery system (GYNECARE VERSAPOINT)
Number of subjects: 133
Study: 23375406

Group type: EXPERIMENTAL
Intervention: Granisetron (1 mg twice daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (twice daily)
Number of subjects: 40
Study: 21991733

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 microg/kg in 20 mL saline
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo solution 20 mL
Number of subjects: 54
Study: 19863364

Group type: EXPERIMENTAL
Intervention: Self-management program 'Living Well with COPD' including a written action plan and case manager support
Number of subjects: 166

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 166
Study: 17098576

Group type: EXPERIMENTAL
Intervention: Green ink
Number of subjects: 2524

Group type: COMPARATOR
Intervention: Black ink
Number of subjects: 2524

Group type: COMPARATOR
Intervention: Brown envelope
Number of subjects: 2524

Group type: EXPERIMENTAL
Intervention: White envelope
Number of subjects: 2524
Study: 15388819

Group type: EXPERIMENTAL
Intervention: Normal protein diet (NPD) (1.20+/‐0.06 g/kg/day)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD) (0.66+/‐0.04 g/kg/day)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Normal subjects (control group)
Number of subjects: 7
Study: 11352441

Group type: EXPERIMENTAL
Intervention: ranitidine 150mg twice daily during a 3‐day pretreatment phase and 1 tablet of ranitidine with a single 400mg dose of moxifloxacin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Maalox 70 10ml given simultaneously with moxifloxacin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Maalox 70 10ml given 4 hours before moxifloxacin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Maalox 70 10ml given 2 hours after moxifloxacin
Number of subjects: 24

Group type: COMPARATOR
Intervention: moxifloxacin alone
Number of subjects: 24
Study: 9398108

Group type: EXPERIMENTAL
Intervention: Carteolol (15 mg/day)
Number of subjects: 20
Study: 7957347

Group type: EXPERIMENTAL
Intervention: N‐isopropyl‐p‐[123I]iodoamphetamine (IMP) SPECT
Number of subjects: 5

Group type: COMPARATOR
Intervention: Age-matched normal controls
Number of subjects: 5
Study: 3297719

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy with Vincristine, Cyclophosphamide, and Prednisone after regional radiotherapy in stage I
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Transdiaphragmatic irradiation after regional radiotherapy in stage II
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: 8 courses of chemotherapy with Adriamycin, VM26, Cyclophosphamide, and Prednisone in stage III and IV
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Follicular lymphoma in stage III and IV
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Stage IV disease due to bone marrow involvement
Number of subjects: 468
Study: 29054720

Group type: EXPERIMENTAL
Intervention: da Vinci Surgical Skills Simulator (dVSSS)
Number of subjects: 39
Study: 26729347

Group type: EXPERIMENTAL
Intervention: Progressive-resisted exercise (PRE) intervention conducted twice weekly for 12 weeks
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual daily activities (Control group)
Number of subjects: 160
Study: 25472808

Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block with ropivacaine 0.375% plus postoperative patient-controlled intravenous analgesia with morphine (TAP group, n = 50)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Perioperative intravenous lidocaine plus postoperative patient-controlled intravenous analgesia with morphine (LIDO group, n = 50)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Postoperative patient-controlled intravenous analgesia with morphine (control group, n = 25)
Number of subjects: 125
Study: 22137366

Group type: EXPERIMENTAL
Intervention: Student Bodies™+ (SB+) intervention
Number of subjects: 126

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 126